The Apnea Risk Evaluation System (ARES) integrates physiological data acquired in-home with clinical history and anthropomorphic data to determine the presence and severity of Obstructive Sleep Apnea (OSA). ARES has been cleared for use by the United States Food and Drug Administration (FDA), and is ISO 13485 certified for Europe and Canada.
ARES Home Sleep test Device integrates:
A sleep-wearable, wireless physiological recorder worn on the forehead that acquires and stores up to 3 nights of nocturnal data. ARES measures blood oxygen saturation (SpO2) and pulse rate (reflectance pulse oximetry), airflow (by nasal cannula connected to a pressure transducer), snoring levels (calibrated acoustic microphone), head movement and head position (accelerometers). When worn in the home, the ARES provides a better profile of the patient's breathing during sleep in his/her normal environment. Audio and visual indicators notify the user when the ARES requires adjustment, thus increasing reliability of the device in the home.
The small size of ARES allows it to be comfortably worn in all sleep positions.
A validated predictor of OSA risk (those in need of a sleep study based on a predicted apnea/hypopnea index > 5 events/hour) and OSA severity (i.e., minimal, mild, moderate or severe) using responses to questions about body type, symptoms of daytime drowsiness, snoring, and other sleep-related characteristics or health conditions associated with OSA. The results can be used to rapidly screen large populations to determine a prior probability of obstructive sleep apnea (OSA). The results are also used to supplement the physiological data obtained in the ARES Sleep Apnea Study.
ARES Patient Friendly:
Sleep testing done in the home,
Reliably self-applied by patient,
Single forehead sensor without wires,
Lightweight and comfortable.
Two nights of fully viewable recordings,
Auto-scoring improves reliability,
Validated in a multi-site clinical study of 280+ patients,
Actigraphy estimation of sleep time.
Half the cost of in-laboratory-test for OSA,
In lab, higher patient/technician ratio,
Use validated questionnaire to screen populations,
Lower cost means more of affected population treated,
Treatment outcome monitoring now affordable.